Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 1 050.31 USD -1.12%
Market Cap: 992.9B USD

Net Margin
Eli Lilly and Co

31%
Current
21%
Average
4.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
31%
=
Net Income
18.4B
/
Revenue
59.4B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Eli Lilly and Co
NYSE:LLY
988.4B USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
514B USD
27%
CH
Roche Holding AG
SIX:ROG
255.9B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
209.3B GBP
16%
CH
Novartis AG
SIX:NOVN
207B CHF
26%
US
Merck & Co Inc
NYSE:MRK
242B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
33%
IE
Endo International PLC
LSE:0Y5F
209B USD
-126%
US
Pfizer Inc
NYSE:PFE
146B USD
16%
FR
Sanofi SA
PAR:SAN
98.7B EUR
21%
No Stocks Found

Eli Lilly and Co
Glance View

Eli Lilly and Co. has long been a stalwart in the pharmaceutical industry, sculpting its trajectory through innovation and strategic acumen. Founded in 1876 by Colonel Eli Lilly, the company has grown from a small chemical firm into a global powerhouse in developing life-changing medications. Its headquarters in Indianapolis, Indiana, serve as a hub of research and development, where groundbreaking scientific exploration meets business strategy. Eli Lilly thrives on its core pillars of innovation in oncology, immunology, and diabetes care, relying on a deep commitment to scientific discovery and patient care. This emphasis allows it to consistently bring cutting-edge treatments to market, boosting its reputation as a leader in pharmaceuticals and maintaining a strong pipeline of drugs that drive future growth. The company's business model is principally built around creating proprietary medications that command premium pricing due to their uniqueness and effectiveness. This model sustains Eli Lilly's revenue through a dual approach: serving mature markets with established products and fueling growth with new launches. Patents on flagship drugs protect these revenue streams, allowing the company to invest substantially in research and development, which in recent years prioritizes personalized medicine and biotechnology. Collaborations with academic institutions and other corporations have also been pivotal, accelerating drug development and expanding Eli Lilly's reach across therapeutic areas. Overall, its ability to navigate regulatory frameworks and maintain robust sales and marketing strategies ensures its medications reach patients globally, securing its financial health and influence within the healthcare landscape.

LLY Intrinsic Value
411.24 USD
Overvaluation 61%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
31%
=
Net Income
18.4B
/
Revenue
59.4B
What is the Net Margin of Eli Lilly and Co?

Based on Eli Lilly and Co's most recent financial statements, the company has Net Margin of 31%.

Back to Top